Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer

Journal of Cellular Physiology

Volumn 231, Issue 2, 2016, Pages 270-274

  Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ACYL COENZYME A DESATURASE; ANDROGEN RECEPTOR COACTIVATOR; ANTINEOPLASTIC AGENT; BICALUTAMIDE; C 646; E1A ASSOCIATED P300 PROTEIN; ENZALUTAMIDE; EPHRIN RECEPTOR A2; FATTY ACID SYNTHASE; FOCAL ADHESION KINASE; GLUCOCORTICOID RECEPTOR; GONADORELIN DERIVATIVE; HYDROXYFLUTAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOSOME; NUCLEAR RECEPTOR COACTIVATOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR JUND; UNCLASSIFIED DRUG; ANDROGEN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; CREBBP PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; EP300 PROTEIN, HUMAN; NUCLEAR RECEPTOR COACTIVATOR;

AMINO TERMINAL SEQUENCE; ANDROGEN SYNTHESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; GENE REPRESSION; HUMAN; LIPOGENESIS; NONHUMAN; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN DOMAIN; SHORT SURVEY; TRANSCRIPTION INITIATION; UPREGULATION; BIOLOGICAL MODEL; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANDROGENS; CELL DIFFERENTIATION; CELL PROLIFERATION; CREB-BINDING PROTEIN; E1A-ASSOCIATED P300 PROTEIN; HUMANS; MALE; MODELS, BIOLOGICAL; NUCLEAR RECEPTOR COACTIVATORS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84944929480     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25099     Document Type: Short Survey

References (49)

1. Agoulnik IU, Vaid A, Bingman 3rd WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. 2005. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65:7959-7967.
2. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE III, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL. 2006. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 66:10594-10602.
3. Altintas DM, Shukla MS, Goutte-Gattat D, Angelov D, Rouault JP, Dimitrov S, Samarut J. 2012. Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells. Mol Endocrinol 26:1531-1541.
4. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z. 2003. The transcriptional co-activator cAMP response element-bidning protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 162:655-663.
5. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, Bartsch G, Offner F, Culig Z, Hobisch A. 2004. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204:159-166.
6. Daniels G, Li Y, Gellert LL, Zhou A, Melamed J, Wu X, Zhang X, Zhang D, Meruelo D, Logan SK, Basch R, Lee P. 2014. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr Relat Cancer 21:127-142.
7. Dasgupta S, Putluri N, Long W, Zhang B, Wang J, Kaushik AK, Arnold JM, Bhowmik SK, Stashi E, Brennan CA, Rajapakshe K, Coarfa C, Mitsiades N, Ittmann MM, Chinnaiyan AM, Sreekumar A, ÓMalley BW. 2015. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J Clin Invest 125:1174-1188.
8. Debes JD, Schmidt LJ, Huang H, Tindall DJ. 2002. P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632-5636.
9. Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. 2005. P300 regulates androgen receptor-independent expression of prostate cancer cells treated chronically with interleukin-6. Cancer Res 65:5965-5973.
10. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M, Lu S. 2006. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 20:2315-2325.
11. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC. 2009. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 8:665-671.
12. Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Zimmermann M, Bond R, He B, Coarfa C, Mitsiades N. 2014. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. 2014. Cancer Res 74:5631-5643.
13. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. 2001. Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85:1928-1936.
14. Gong J, Zhu J, Goodman OB, Jr., Pestell RG, Schlegel PN, Nanus DM, Shen R. 2006. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 25:2011-2021.
15. Gross M, Liu B, Tan J, French FS, Carey M, Shuai K. 2001. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 20:3880-3887.
16. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. 2003. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 24:2466-2477.
17. He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wie L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedova DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, ÓMalley BW, Mitsiades N. 2014. GATA2 facilitates steroid receptor coactivator to the androgen receptor complex. Proc Natl Acad Sci USA 111:18261-18266.
18. Heemers HV, Sebo TJ, Debes J, Regan KM, Raclav KA, Murphy LM, Hobisch A, Culig Z, Tindall DJ. 2007a. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67:3422-3430.
19. Heemers HV, Regan KM, Dehm SM, Tindall DJ. 2007b. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: Evidence for a role for serum response factor in prostate cancer. Cancer Res 67:10592-10599.
20. Heitzer MD, DeFranco DB. 2006. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. 2006. Cancer Res 66:7326-7333.
21. Jaganathan A, Chaurasia P, Xiao GQ, Philizaire M, Lv X, Yao S, Burnstein KL, Liu DP, Levine AC, Mujtaba S. 2014. Coactivator MYST1 regulates nuclear factor-kappaB and androgen receptor functions during proliferation of prostate cancer cells. Mol Endocrinol 28:872-875.
22. Lyons LS, Burnstein KL. 2006. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 20:1061-1072.
23. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schüle R, Buettner R. 2006. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half domain protein 2 predic risk of prostate cancer recurrence. Cancer Res 66:11341-11347.
24. Kaulfuss S, Grzmil M, Hemmerleien B, Thelen P, Schweyer S, Neesen J, Bubendorf L, Glass AG, Jarry H, Auber B, Burfeind P. 2008. Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells. Mol Endocrinol 22:1606-1621.
25. Li X, Martinez-Ferrer M, Botta V, Uwamriya C, Banerjee J, Bhowmick NA. 2011. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. 2011. Oncogene 30:167-177.
26. Ligr M, Li Y, Zou X, Daniels G, Melamed J, Peng Y, Wang W, Wang J, Ostrer H, Pagano M, Wang Z, Garabedian MJ, Lee P. 2010. Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol 176:1891-1900.
27. Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ, Wang LH. 2012. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res 72:3000-3009.
28. Mäki HE, Waltering KK, Wallen MJ, Martikainen PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T. 2006. Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate 66:1391-1398.
29. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig Z. 2009. Interleukin-6 stimulation of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16:155-169.
30. McGrath MJ, Binge LC, Sriratana A, Wang H, Robinson PA, Pook D, Fedele CG, Brown S, Dyson JM, Cottle DL, Cowling BS, Niranjan B, Risbridger GP, Mitchell CA. 2013. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. Cancer Res 73:5066-5079.
31. Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G. 2010. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Res 70:4560-4568.
32. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. 1998a. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 95:11083-11088.
33. Miyamoto H, Yeh S, Wilding G, Chang C. 1998b. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95:7379-7384.
34. Nakka M, Agoulnik IU, Weigel NL. 2013. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. 2013. Int J Biochem Cell Biol 45:763-772.
35. Peacock SO, Fahrenholtz CD, Burnstein KL. 2012. Vav3 enhances androgen receptor splice variant activity and is critical for prostate cancer growth and survival. Mol Endocrinol 26:1967-1979.
36. Peng Y, Chen F, Melamed J, Chiriboga L, Wei J, Kong X, McLeod M, Li Y, Li CX, Feng A, Garabedian MJ, Wang Z, Roeder RG, Lee P. 2008. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci USA 105:5236-5241.
37. Qin J, Lee HJ, Wu SP, Lin SC, Lanz RB, Creighton CJ, DeMayo FJ, Tsai SY, Tsai MJ. 2014. Androgen deprivation -induced NcoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest 124:5013-5026.
38. Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL. 2012. A novel nuclear role for the Vav3 nucleotide exchange in androgen receptor coactivation in prostate cancer. 2012. Oncogene 31:716-727.
39. Santer FR, Höschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, Parson W, Myers DJ, Cole PA, Culig Z. 2011. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10:1644-1655.
40. Santer FR, Erb HH, Oh SJ;, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z. 2015. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. Oncotarget. 6:6105-6122.
41. Shiota M, Yokomizo A, Masubuchi D, Tada Y, Inokuchi J, Eto M, Uchiumi T, Fujimoto N, Naito S. 2010. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate 70:540-554.
42. Tien JC, Zhou S, Xu J. 2009. The role of SRC-1 in murine prostate carcinogenesis is nonessential due to a possible compensation of SRC-3/AIB1 overexpression. Int J Biol Sci 5:256-264.
43. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. 2002. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-38094.
44. Walsh CA, Bolger JC, Byrne C, Cocchiglia S, Hao Y, Fagan A, Qin L, Cahalin A, McCartan D, McIlroy M, ÓGaora P, Xu J, Hill Ad, Young LS. 2014. Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis. Cancer Res 74:2533-2544.
45. Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H. 2014. P300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. 2014. Cancer Res 74:1870-1880.
46. Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, Chen HW. 2009. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res 69:3339-3346.
47. Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ. 2006. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. 2006. Cancer Res 66:11039-11046.
48. Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, di Sant-Agnese PA, Chang C. 2007. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 21:343-358.
49. Yeh S, Miyamoto H, Shima H, Chang C. 1998. From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 95:5527-5532.